1. HBW Insight

Pfizer Expects OTC Nexium Will Launch With Market Exclusivity

 
• By Malcolm Spicer

Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.

Pfizer Inc. expects to launch OTC proton pump inhibitor Nexium 24HR with three-year market exclusivity, following FDA’s approval on March 28 of a new drug application for the 20 mg esomeprazole product.

Nexium 24HR is indicated for frequent heartburn, defined as happening two or more days a week, in consumers age 18 years and older

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America